DRIVE-SHIFT resistance profile

DELSTRIGO® DRIVE-SHIFT resistance profile

0 development of resistance to Doravirine shown in a 48-week study of patients with HIV-1:^1,*

• No patient developed genotypic or phenotypic resistance to doravirine, 3TC, or TDF during treatment with DELSTRIGO® in either the ISG (n=447) or DSG (n=209).¹
• One patient developed an RT M184M/I mutation and phenotypic resistance to 3TC and FTC during treatment with their baseline regimen.

Activity in the presence of NNRTI mutations (RT K103N, G190A, or Y181C) shown^1,*

None of the 24 subjects (11 ISG [Day 1], 13 DSG [Week 24]) with baseline NNRTI mutations (RT K103N, G190A, or Y181C) experienced virologic failure through Week 48 or at time of discontinuation.¹

* Clinical significance has not been established.

3TC=lamivudine; TDF=tenofovir disoproxil fumarate; ISG=immediate switch group; DSG=delayed switch group; RT=reverse transcriptase; NNRTI=non-nucleoside reverse transcriptase inhibitor

Reference: 1. DELSTRIGO® Product Monograph. Merck Canada Inc. December 10, 2024.

CA-DOR-00155